DexCom (NASDAQ:DXCM) Upgraded at Baird R W

DexCom (NASDAQ:DXCM) was upgraded by equities researchers at Baird R W from a “hold” rating to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

A number of other research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Wells Fargo & Company boosted their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $104.00 in a research note on Thursday. Royal Bank of Canada lowered their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Raymond James dropped their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Trading Up 5.5 %

Shares of DexCom stock opened at $84.84 on Thursday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a market capitalization of $33.14 billion, a price-to-earnings ratio of 50.80, a PEG ratio of 2.00 and a beta of 1.12. The firm’s 50-day moving average price is $77.89 and its two-hundred day moving average price is $78.41.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of DXCM. Dimensional Fund Advisors LP boosted its position in DexCom by 41.3% during the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company’s stock valued at $104,282,000 after acquiring an additional 268,802 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of DexCom by 2.3% in the 2nd quarter. Mutual of America Capital Management LLC now owns 55,054 shares of the medical device company’s stock valued at $6,242,000 after purchasing an additional 1,229 shares during the period. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of DexCom by 9.4% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,976 shares of the medical device company’s stock valued at $678,000 after purchasing an additional 512 shares in the last quarter. Kentucky Retirement Systems grew its stake in DexCom by 2.4% during the second quarter. Kentucky Retirement Systems now owns 29,968 shares of the medical device company’s stock worth $3,398,000 after purchasing an additional 691 shares during the period. Finally, MQS Management LLC acquired a new stake in DexCom during the second quarter worth approximately $266,000. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.